Huntsman Cancer Institute (HCI) at the University of Utah (U of U) is the only National Cancer Institute (NCI)-Designated Cancer Center in the State of Utah. It serves as the advanced cancer care center for the State, with a dedicated cancer specialty hospital, a statewide network of Cancer Learning Centers, training programs for cancer researchers and health care professionals, and a major commitment to cancer research -- with depth and breadth that spans basic laboratory research; clinical research, including early phase clinical trials; and prevention, control, and population-based research. HCI is also the only NCI-Designated Cancer Center in the five-state Intermountain West (Utah, Idaho, Montana, Nevada, and Wyoming). HCI fills a critical role in the national cancer program by serving this large geographical area and by conducting research that addresses aspects of the special cancer burden of rural and frontier populations and Native American groups that reside in the Intermountain West. Our Cancer Center has 136 members drawn from 27 academic departments in six colleges at the U of U. The members are supported by $54.8M in total extramural cancer research funding. HCI research is organized into four Research Programs that provide an environment of cancer focus and collaborative exchange: ? Nuclear Control of Cell Growth and Differentiation ? Cell Response and Regulation ? Experimental Therapeutics ? Cancer Control and Population Sciences HCI's Disease-Oriented Research Teams bring together members who share common disease-focused interests, providing an additional organizational structure to support transdisciplinary cancer research. HCI members published 1,419 cancer-focused, peer-reviewed publications from 2009-2013, of which 78% are collaborative, either within the Cancer Center or with external research partners. Support is requested for six HCI Shared Resources that provide access to specialized instrumentation, assays, services, research materials, and expert consultation and collaboration. These Shared Resources include the following: ? Utah Population Database ? Genetic Counseling ? Research Informatics ? Cancer Biostatistics ? Biorepository and Molecular Pathology ? High-Throughput Genomics and Bioinformatic Analysis In summary, HCI requests funds to support Years 26-30 of our Cancer Center Support Grant (CCSG), under the leadership of Mary Beckerle, Ph.D., HCI's Chief Executive Officer and Director. CCSG funding will support expenses associated with Cancer Center Shared Resources, Clinical Protocol and Data Management, Protocol Review and Monitoring, Program Leadership, Administration, and Developmental Funds.

Public Health Relevance

The genetic understanding of cancer has led to enhanced individual risk assessment, improved screening guidelines, and improved outcomes based on cancer prevention, early detection, and, in some cases, targeted therapy. Huntsman Cancer Institute is positioned to make exceptional contributions in this individualized oncology arena. The Cancer Center has a unique research resource to support genetic and population studies (the Utah Population Database), a compelling history of genetic discovery in oncology, and a strategic plan to accelerate translational advances from this platform. Through the work supported by our Cancer Center Support Grant, we aim to accelerate the progress of high-impact scientific discoveries across basic laboratory; clinical; and prevention, cancer control, and population-based research, as well as to disseminate these research findings to improve outcomes for individuals impacted by cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA042014-26
Application #
8853734
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-05-09
Project End
2020-04-30
Budget Start
2015-07-08
Budget End
2016-04-30
Support Year
26
Fiscal Year
2015
Total Cost
$1,639,000
Indirect Cost
$539,000
Name
University of Utah
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Fleming, Aaron M; Zhu, Judy; Ding, Yun et al. (2018) Human DNA Repair Genes Possess Potential G-Quadruplex Sequences in Their Promoters and 5'-Untranslated Regions. Biochemistry 57:991-1002
Hellwig, Sabine; Nix, David A; Gligorich, Keith M et al. (2018) Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing. PLoS One 13:e0197333
Martin, Christopher; Leiser, Claire L; O'Neil, Brock et al. (2018) Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst 110:527-533
Mollaoglu, Gurkan; Jones, Alex; Wait, Sarah J et al. (2018) The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment. Immunity 49:764-779.e9
Sorenson, Reed S; Deshotel, Malia J; Johnson, Katrina et al. (2018) Arabidopsis mRNA decay landscape arises from specialized RNA decay substrates, decapping-mediated feedback, and redundancy. Proc Natl Acad Sci U S A 115:E1485-E1494
Polanco, Edward R; Western, Nicholas; Zangle, Thomas A (2018) Fabrication of Refractive-index-matched Devices for Biomedical Microfluidics. J Vis Exp :
Camolotto, Soledad A; Pattabiraman, Shrivatsav; Mosbruger, Timothy L et al. (2018) FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer. Elife 7:
Nevala-Plagemann, Christopher; Francis, Samual; Cavalieri, Courtney et al. (2018) Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open 3:e000386
Li, Lian; Yang, Jiyuan; Wang, Jiawei et al. (2018) Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics. ACS Nano 12:3658-3670
Wu, Yelena P; Nagelhout, Elizabeth; Aspinwall, Lisa G et al. (2018) A novel educational intervention targeting melanoma risk and prevention knowledge among children with a familial risk for melanoma. Patient Educ Couns 101:452-459

Showing the most recent 10 out of 1193 publications